<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the occurrence and clinical significance of <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation (<z:mp ids='MP_0003674'>oxidative stress</z:mp>) in <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> characterized by vascular involvement </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Plasma <z:chebi fb="0" ids="34505">8-epi-PGF2alpha</z:chebi> (<z:mp ids='MP_0003674'>oxidative stress</z:mp> marker) was measured by gas chromatography-mass spectrometry in 36 patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), 13 with systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> (SSc), 13 with systemic <z:hpo ids='HP_0002633'>vasculitis</z:hpo> [Wegener's <z:hpo ids='HP_0002955'>granulomatosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">WG</z:e>), n = 4; <z:e sem="disease" ids="C0008728" disease_type="Disease or Syndrome" abbrv="">Churg Strauss syndrome</z:e> (CSS), n = 3; <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet syndrome</z:e>, n = 6], 12 with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) and in 23 healthy controls (n = 23) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: <z:chebi fb="0" ids="34505">8-epi-PGF2alpha</z:chebi> levels were higher in patients with SLE (P = 0.007), SSc (P &lt; 0.001) and <z:hpo ids='HP_0002633'>vasculitis</z:hpo> (P = 0.001) than in controls </plain></SENT>
<SENT sid="3" pm="."><plain>In SLE, a positive Coombs' test and arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> independently predicted <z:chebi fb="0" ids="34505">8-epi-PGF2alpha</z:chebi> concentrations (P = 0.004 and P = 0.001, respectively) </plain></SENT>
<SENT sid="4" pm="."><plain>SLE patients not taking <z:chebi fb="2" ids="8378">prednisolone</z:chebi> showed higher <z:chebi fb="0" ids="34505">8-epi-PGF2alpha</z:chebi> concentrations than SLE patients on <z:chebi fb="2" ids="8378">prednisolone</z:chebi> (P = 0.02) </plain></SENT>
<SENT sid="5" pm="."><plain>In the latter group, a dose response relationship was noted between <z:chebi fb="0" ids="34505">8-epi-PGF2alpha</z:chebi> and steroid dosage (r = 0.6, P = 0.0003) </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">WG</z:e> and CSS, <z:chebi fb="0" ids="34505">8-epi-PGF2alpha</z:chebi> concentrations correlated with disease activity (r = 0.8, P = 0.01) and were higher than in patients with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet disease</z:e> (P = 0.003) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: <z:mp ids='MP_0003674'>Oxidative stress</z:mp> may be pathogenetically relevant in some autoimmune <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> with vascular involvement </plain></SENT>
<SENT sid="8" pm="."><plain>Amelioration of some clinical manifestations of these diseases may be envisaged by targeting <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation with dietary or pharmacological <z:chebi fb="11" ids="22586">antioxidants</z:chebi> </plain></SENT>
</text></document>